Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Effectiveness between the adalimumab biosimilars (Amjevita and Imraldi) and the original brand-name version (Humira) was comparable both in new users and for patients switching from the original ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

For example, a UnitedHealth Group segment runs Optum Rx and a new private-label business, Nuvaila. Optum Rx's 2025 premium and select formularies have the low list price of Humira biosimilar ...

a biosimilar for AbbVie's Humira (adalimumab) recently approved as Hyrimoz. A new version is set for launch in the US under a Cordavis label in early 2024 at an 80% discount to the original brand ...

Humira is starting to feel the effects of lower ... Last month, the FDA added a boxed warning to Xeljanz’ label for increased risk of potentially fatal blood clots, while Olumiant has been ...

J&J in its lawsuit said Humira's market erosion was illustrative of the harm Samsung Bioepis' private label deal could have. Stelara biosimilars launched in Europe, Canada and a few other markets ...